Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Payables (2021 - 2025)

Amylyx Pharmaceuticals has reported Payables over the past 5 years, most recently at $3.5 million for Q4 2025.

  • Quarterly results put Payables at $3.5 million for Q4 2025, up 19.73% from a year ago — trailing twelve months through Dec 2025 was $3.5 million (up 19.73% YoY), and the annual figure for FY2025 was $3.5 million, up 19.73%.
  • Payables for Q4 2025 was $3.5 million at Amylyx Pharmaceuticals, down from $5.3 million in the prior quarter.
  • Over the last five years, Payables for AMLX hit a ceiling of $24.7 million in Q2 2023 and a floor of $1.5 million in Q3 2024.
  • Median Payables over the past 5 years was $6.3 million (2022), compared with a mean of $8.7 million.
  • Biggest five-year swings in Payables: plummeted 86.68% in 2024 and later soared 259.05% in 2025.
  • Amylyx Pharmaceuticals' Payables stood at $4.4 million in 2021, then soared by 43.12% to $6.3 million in 2022, then skyrocketed by 252.58% to $22.1 million in 2023, then plummeted by 86.68% to $2.9 million in 2024, then increased by 19.73% to $3.5 million in 2025.
  • The last three reported values for Payables were $3.5 million (Q4 2025), $5.3 million (Q3 2025), and $3.3 million (Q2 2025) per Business Quant data.